Targeting CD38 and BCMA in Myeloma: Evidence and Enhanced Outcomes with Innovative Therapies

Stay up-to-date on the latest safety and efficacy data of CD38- and BCMA-targeting therapies being used to treat multiple myeloma while prioritizing patient safety and toxicity management and learn how providers can address disparities in myeloma care, through an expert-written ClinicalThought commentary and a CME-certified on-demand webcast with an accompanying slideset.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Sanofi.

Sanofi